Videos of the Month

Drug-Loaded 3D Printed Films

Drug-loaded 3D-printed films could change cancer treatments forever as world first research from the University of South Australia shows the new films kill liver cancer cells by more than 80 percent, with less systematic toxicities of chemotherapy. Created from gels, the biodegradable 3D printed films are loaded with tailored doses of anti-cancer drugs 5-fluorouracil (5FU) and cisplatin (Cis) and placed at the exact surgical site where a cancer has been removed, localizing drugs to the affected area while limiting the undesirable side effects of traditional chemotherapy.

Visit Here

Discovery Boosts Potential of New Cancer-Fighting Drugs

Scientists at Scripps Research have uncovered a critical feature that a promising new class of cancer drugs, known as CELMoDs, needs to be effective. CELMoDs are designed to attack cancer in a novel way, by binding to a regulatory protein called cereblon, which then triggers the degradation of key cancer-driving proteins.

Visit Here

The Bridge Recombination Mechanism — Next Generation Genome Design

Researchers have discovered the bridge recombinase mechanism, a precise and powerful tool to recombine and rearrange DNA in a programmable way. Going far beyond programmable genetic scissors like CRISPR, the bridge recombinase mechanism enables scientists to specify not only the target DNA to be modified, but also the donor material to be recognized, so they can insert new, functional genetic material, cut out faulty DNA, or invert any two sequences of interest.

Visit Here

Immunotherapy: Drug Harnesses Immune System Against Cancer

Certain types of immune cells called regulatory T-cells, while vital for a balanced immune system, can hinder the cancer-killing process. Targeting these cells without affecting other immune cells in the past has been difficult. A new drug can stop regulatory T-cells from working while leaving other immune cells intact to fight the cancer cells. Watch this drug in action in this short animation.

Visit Here